MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do…
Echtzeit-Aktienkurs Acorda Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Acorda Therapeutics Inc. Aktie
Areteia Therapeutics gibt die Ernennung von Donald J. Hayden, Jr. und Ian F. Smith in den Vorstand bekannt
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“) gab heute bekannt, dass der Vorstand mit sofortiger Wirkung Donald J. Hayden,…
Areteia Therapeutics präsentiert auf der 43. jährlichen J.P. Morgan Healthcare Conference am Dienstag, den 14. Januar 2025
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“), ein Biotechnologieunternehmen im klinischen Stadium, das neuartige Entzündungs- und Immuntherapien entwickelt, mit…
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical…
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Merz Therapeutics erwirbt Produkte von Acorda Therapeutics in den Therapiegebieten Multiple Sklerose und Morbus Parkinson im Wert von 185 Mio. USD
FRANKFURT, Deutschland--(BUSINESS WIRE)--Merz Therapeutics gab heute den erfolgreichen Erwerb von INBRIJA® (Levodopa-Pulver zur Inhalation) und (F)AMPYRA® (Fampridin) von Acorda Therapeutics,…
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a…
Acorda Therapeutics announces delisting from Nasdaq
…
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported…
Acorda Therapeutics announces Nasdaq delisting notification
…
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical…
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…